Zhong Yuan Bio-Technology Holdings Ltd

Zhong Yuan Bio-Technology Holdings Ltd. (OTC: ZHYBF) is a Cayman Islands investment holding company that has undergone multiple name and domicile changes since its original Delaware incorporation: formerly known as Agate Island Acquisition Corp, then China BioTech Co Corp, then China Biotech Holdings Ltd (Delaware), before effecting a domicile change from Delaware to the Cayman Islands on August 21, 2018, at which point the company became Zhong Yuan Bio-Technology Holdings Limited. The company is principally engaged in the development and sale of health supplements focusing on neurological health, brain disease diagnostics, and plant-derived nutritional supplements in China, operating through a complex subsidiary chain that extends from the Cayman Islands holding company through a Seychelles intermediate company, a Hong Kong subsidiary, a wholly foreign-owned enterprise (WFOE) in China, and ultimately through Bao-Feng Bio-Technology (Beijing) Limited — the principal Chinese operating entity that conducts the company's commercial activities.<br><br>The company's product portfolio is anchored by its 'Muzhiyuan Neuro Enhancer' branded health supplements, which draw on plant-derived nervonic acid — a fatty acid found naturally in nerve cell membranes and proposed to support neurological function and brain health — as a key active ingredient. In addition to nervonic acid-based health supplements, the company has been involved in the development of new drugs for neurological disorders and brain disease detection kits, addressing the diagnostic and therapeutic needs of patients and healthcare consumers managing neurological health conditions. China's health supplement market has experienced strong growth driven by the aging population, rising middle-class health consciousness, traditional Chinese medicine cultural acceptance of herbal and botanical health products, and increasing consumer spending on preventive health and wellness products.<br><br>Zhong Yuan Bio-Technology Holdings Ltd. has filed multiple Form F-1 and Form F-1/A registration statement amendments with the Securities and Exchange Commission over the period from 2020 through 2024, reflecting the company's sustained effort to complete a registered public offering in the United States and achieve a listed or OTC-quoted status that provides U.S. investors with a transparent, regulated investment vehicle. The company is classified under SIC code 2833 (pharmaceutical preparations — medicinal chemicals and botanical products) and is traded on the OTC market under the ticker symbol ZHYBF. As a neurological health supplement company operating through a Cayman Islands/China structure and pursuing U.S. capital market access through repeated SEC registration efforts, Zhong Yuan Bio-Technology represents the class of Chinese life sciences and health supplement companies seeking to establish U.S. public market presence through the SEC registration pathway.